Dr. Chapin on Impact of Active Surveillance in Field of Prostate Cancer

Video

In Partnership With:

Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses impact of active surveillance in the field of prostate cancer.

Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses impact of active surveillance in the field of prostate cancer.

There has been a large, national increase in the number of patients going onto active surveillance programs, Chapin explains. Compared with the smaller proportion seen previously, researchers now are seeing that up to 40% of men who are diagnosed with low-risk tumors are going onto an active surveillance program.

Additionally, he says, the community is recognizing that not all prostate cancers are the same. Some prostate cancers are indolent and are unlikely to cause significant problems. Patients are becoming more aware of that; therefore, they are seeking out other options and not just choosing to go with active treatment.

Related Videos
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS